KR20200023528A - 갑상선 호르몬 유사체 및 이의 다형의 합성 방법 - Google Patents

갑상선 호르몬 유사체 및 이의 다형의 합성 방법 Download PDF

Info

Publication number
KR20200023528A
KR20200023528A KR1020207005528A KR20207005528A KR20200023528A KR 20200023528 A KR20200023528 A KR 20200023528A KR 1020207005528 A KR1020207005528 A KR 1020207005528A KR 20207005528 A KR20207005528 A KR 20207005528A KR 20200023528 A KR20200023528 A KR 20200023528A
Authority
KR
South Korea
Prior art keywords
compound
acid
batch
less
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207005528A
Other languages
English (en)
Korean (ko)
Inventor
디. 케이트 헤스터
로버트 제이. 두구이드
마르타 켈리
안나 채스노프
강 동
에드윈 엘. 크로우
레베카 타우브
챨스 에이치. 레이놀즈
덕 순 최
리안헤 슈
핑 왕
Original Assignee
마드리갈 파마슈티칼스, 인크.
에프. 호프만-라 로슈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마드리갈 파마슈티칼스, 인크., 에프. 호프만-라 로슈 리미티드 filed Critical 마드리갈 파마슈티칼스, 인크.
Priority to KR1020217019940A priority Critical patent/KR102363776B1/ko
Publication of KR20200023528A publication Critical patent/KR20200023528A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020207005528A 2012-09-17 2013-09-17 갑상선 호르몬 유사체 및 이의 다형의 합성 방법 Ceased KR20200023528A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217019940A KR102363776B1 (ko) 2012-09-17 2013-09-17 갑상선 호르몬 유사체 및 이의 다형의 합성 방법

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261702137P 2012-09-17 2012-09-17
US61/702,137 2012-09-17
US201361790432P 2013-03-15 2013-03-15
US61/790,432 2013-03-15
PCT/US2013/060177 WO2014043706A1 (en) 2012-09-17 2013-09-17 Method of synthesizing thyroid hormone analogs and polymorphs thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187034908A Division KR102138750B1 (ko) 2012-09-17 2013-09-17 갑상선 호르몬 유사체 및 이의 다형의 합성 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217019940A Division KR102363776B1 (ko) 2012-09-17 2013-09-17 갑상선 호르몬 유사체 및 이의 다형의 합성 방법

Publications (1)

Publication Number Publication Date
KR20200023528A true KR20200023528A (ko) 2020-03-04

Family

ID=50278769

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020157009807A Active KR101966490B1 (ko) 2012-09-17 2013-09-17 갑상선 호르몬 유사체 및 이의 다형의 합성 방법
KR1020207005528A Ceased KR20200023528A (ko) 2012-09-17 2013-09-17 갑상선 호르몬 유사체 및 이의 다형의 합성 방법
KR1020187034908A Active KR102138750B1 (ko) 2012-09-17 2013-09-17 갑상선 호르몬 유사체 및 이의 다형의 합성 방법
KR1020217019940A Active KR102363776B1 (ko) 2012-09-17 2013-09-17 갑상선 호르몬 유사체 및 이의 다형의 합성 방법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020157009807A Active KR101966490B1 (ko) 2012-09-17 2013-09-17 갑상선 호르몬 유사체 및 이의 다형의 합성 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020187034908A Active KR102138750B1 (ko) 2012-09-17 2013-09-17 갑상선 호르몬 유사체 및 이의 다형의 합성 방법
KR1020217019940A Active KR102363776B1 (ko) 2012-09-17 2013-09-17 갑상선 호르몬 유사체 및 이의 다형의 합성 방법

Country Status (23)

Country Link
US (8) US9266861B2 (enExample)
EP (4) EP4406594B1 (enExample)
JP (8) JP6616688B2 (enExample)
KR (4) KR101966490B1 (enExample)
CN (2) CN108101851A (enExample)
AR (1) AR092872A1 (enExample)
AU (1) AU2013315017C1 (enExample)
BR (2) BR122021024202B1 (enExample)
CA (3) CA3090070C (enExample)
DK (3) DK2895466T3 (enExample)
ES (2) ES2907926T3 (enExample)
FI (1) FI4406594T3 (enExample)
IL (7) IL320269A (enExample)
IN (1) IN2015DN03133A (enExample)
MX (2) MX395148B (enExample)
MY (1) MY170520A (enExample)
NZ (2) NZ705827A (enExample)
PT (1) PT4406594T (enExample)
RU (2) RU2668960C2 (enExample)
SG (3) SG10201705984XA (enExample)
TW (4) TWI804870B (enExample)
WO (1) WO2014043706A1 (enExample)
ZA (1) ZA201501795B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201705984XA (en) * 2012-09-17 2017-08-30 Madrigal Pharmaceuticals Inc Method of synthesizing thyroid hormone analogs and polymorphs thereof
IL266054B2 (en) * 2016-10-18 2023-10-01 Madrigal Pharmaceuticals Inc Methods for treating liver disorders or lipid disorders using a THR-BETA agonist
CN111646979B (zh) * 2018-01-23 2021-08-31 深圳市塔吉瑞生物医药有限公司 取代的哒嗪酮化合物
JP7181386B2 (ja) 2018-06-12 2022-11-30 スーチョワン ハイスコ ファーマスーティカル カンパニー リミテッド 甲状腺ホルモン受容体アゴニスト及びその用途
US20210292304A1 (en) * 2018-06-22 2021-09-23 Hinova Pharmaceuticals Inc. Deuterated mgl-3196 compound and use thereof
TW202019914A (zh) * 2018-07-02 2020-06-01 美商瑪德瑞高製藥公司 ２-（３，５-二氯-４-（（５-異丙基-６-側氧基-１，６-二氫噠嗪-３-基）氧）苯基）-３，５-二側氧基-２，３，４，５-四氫-１，２，４-三嗪-６-腈之固體型式
CN119552152A (zh) * 2018-10-12 2025-03-04 益方生物科技(上海)股份有限公司 甲状腺激素受体激动剂
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
EP3927693A4 (en) 2019-02-21 2023-04-05 Nanjing Ruijie Pharma Co., Ltd. NOVEL COMPOUNDS AND THEIR USES AS THYROID HORMONE RECEPTOR AGONISTS
SG11202111552YA (en) * 2019-05-08 2021-11-29 Aligos Therapeutics Inc MODULATORS OF THR-ß AND METHODS OF USE THEREOF
TW202108556A (zh) * 2019-05-10 2021-03-01 大陸商深圳微芯生物科技股份有限公司 一種噠嗪酮衍生物及其應用
WO2020239076A1 (zh) * 2019-05-29 2020-12-03 南京明德新药研发有限公司 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用
WO2021043185A1 (en) * 2019-09-04 2021-03-11 Sunshine Lake Pharma Co., Ltd. A compound as a thyroid hormone beta receptor agonist and use thereof
CN114375193B (zh) 2019-09-12 2024-05-14 拓臻制药公司 甲状腺激素受体β激动剂化合物
WO2021063367A1 (zh) * 2019-09-30 2021-04-08 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
CN112707892A (zh) * 2019-10-24 2021-04-27 苏州泽璟生物制药股份有限公司 哒嗪酮或哒嗪类化合物及其衍生物和药物组合物
EP4083024A4 (en) * 2019-11-26 2023-11-01 KPC Pharmaceuticals, Inc. 1,2,4-TRIAZINE-3,5-DIONE COMPOUND, METHOD FOR PRODUCTION THEREOF AND USE THEREOF
WO2021121210A1 (zh) * 2019-12-16 2021-06-24 江苏恒瑞医药股份有限公司 并环类衍生物、其制备方法及其在医药上的应用
CN114787153A (zh) 2019-12-26 2022-07-22 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
CN116056709A (zh) * 2020-08-27 2023-05-02 益方生物科技(上海)股份有限公司 哒嗪酮化合物
AU2021341182A1 (en) * 2020-09-10 2023-04-27 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of resmetirom, preparation method therefor, and use thereof
US20230364099A1 (en) 2020-10-19 2023-11-16 Teva Pharmaceuticals International Gmbh Solid state forms of resmetirom
CN114437042A (zh) * 2020-11-03 2022-05-06 深圳微芯生物科技股份有限公司 酞嗪类化合物的晶型及其制备方法
CN114437034A (zh) * 2020-11-06 2022-05-06 深圳微芯生物科技股份有限公司 一种酞嗪类化合物的可药用盐、晶型及其制备方法
MX2023009024A (es) * 2021-02-01 2023-08-09 Madrigal Pharmaceuticals Inc Combinaciones terapeuticas de rosuvastatina y resmetirom para el tratamiento de trastornos hepaticos o trastornos lipidicos.
CN114907327A (zh) * 2021-02-10 2022-08-16 杭州领业医药科技有限公司 Resmetirom的晶型及其制备方法和用途
CN115073429A (zh) * 2021-03-15 2022-09-20 昆药集团股份有限公司 一种1，2，4-三嗪-3，5-二酮类化合物的盐型、晶型及其制备方法
EP4578499A3 (en) 2021-09-27 2025-09-17 Madrigal Pharmaceuticals, Inc. Resmetirom for reducing liver volume
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
TW202506131A (zh) 2023-04-07 2025-02-16 美商拓臻製藥公司 ＧＬＰ－１Ｒ及ＴＨＲβ激動劑之組合以及其使用方法
CN116768802B (zh) * 2023-05-25 2025-11-21 杭州科巢生物科技有限公司 一种瑞司美替罗的合成方法
WO2024263714A1 (en) 2023-06-22 2024-12-26 Madrigal Pharmaceuticals, Inc. BIOMARKERS FOR TREATING LIVER DISORDERS WITH THR-β AGONISTS AND RELATED USES
CN119613386A (zh) * 2023-09-14 2025-03-14 杭州科巢生物科技有限公司 一种瑞司美替罗1,4-二氧六环溶剂化合物及其制备方法
CN117263870A (zh) * 2023-09-21 2023-12-22 江西同和药业股份有限公司 一种Resmetirom关键中间体III的制备方法
WO2025083699A2 (en) 2023-10-16 2025-04-24 Cipla Limited Resmetirom polymorphs and process thereof
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025164161A1 (ja) * 2024-01-29 2025-08-07 シオノギファーマ株式会社 カンナビジオールの溶媒和物及びカンナビジオールの精製方法
WO2025171032A1 (en) 2024-02-06 2025-08-14 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease
US12377104B1 (en) 2024-02-06 2025-08-05 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease
WO2025191457A1 (en) * 2024-03-13 2025-09-18 Morepen Laboratories Limited Process for the preparation of pyridazinone derivative
CN119306670A (zh) * 2024-10-12 2025-01-14 北京海美桐医药科技有限公司 瑞司美替罗中间体、其合成方法和瑞司美替罗的合成方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5615272A (en) * 1979-07-17 1981-02-14 Ishihara Sangyo Kaisha Ltd N-benzoyl-n'-phenylurea compound, its preparation, and insecticide containing the same
GB0028429D0 (en) 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
EP1587830B1 (en) 2003-01-28 2009-07-08 Academisch Ziekenhuis Leiden Peptide inhibitors of toxins derived from ll-37
CA2518823A1 (en) 2003-03-24 2004-10-07 F.Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
ITRM20030363A1 (it) 2003-07-24 2005-01-25 Fernando Goglia Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
US7807647B2 (en) * 2004-06-01 2010-10-05 Pronai Therapeutics, Inc. Methods and compositions for cancer therapy
US20060229267A1 (en) * 2004-06-01 2006-10-12 Reza Sheikhnejad Methods and compositions for the inhibition of gene expression
JP5337375B2 (ja) 2004-11-02 2013-11-06 ノースウェスタン ユニバーシティ ピリダジン化合物、組成物および方法
KR100965006B1 (ko) 2005-07-21 2010-06-21 에프. 호프만-라 로슈 아게 갑상선 호르몬 수용체 작용제로서 피리다진온 유도체
UA98962C2 (ru) 2007-06-06 2012-07-10 Торрент Фармасьютикалз Лтд. Аналоги тиреоидного гормона, фармацевтическая композиция, которая их содержит, способ лечения с их использованием, их применение и способ получения
US8076334B2 (en) * 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
SG10201705984XA (en) 2012-09-17 2017-08-30 Madrigal Pharmaceuticals Inc Method of synthesizing thyroid hormone analogs and polymorphs thereof
US8858502B2 (en) 2012-10-10 2014-10-14 Alcon Research, Ltd. Systems and methods for external pressure sensing
RU2016133471A (ru) 2014-02-14 2018-03-19 Семпра Фармасьютикалс, Инк. Композиции и способы для лечения диабета и заболеваний печени
IL266054B2 (en) 2016-10-18 2023-10-01 Madrigal Pharmaceuticals Inc Methods for treating liver disorders or lipid disorders using a THR-BETA agonist
JP7181386B2 (ja) 2018-06-12 2022-11-30 スーチョワン ハイスコ ファーマスーティカル カンパニー リミテッド 甲状腺ホルモン受容体アゴニスト及びその用途
TW202019914A (zh) 2018-07-02 2020-06-01 美商瑪德瑞高製藥公司 ２-（３，５-二氯-４-（（５-異丙基-６-側氧基-１，６-二氫噠嗪-３-基）氧）苯基）-３，５-二側氧基-２，３，４，５-四氫-１，２，４-三嗪-６-腈之固體型式
CN119552152A (zh) 2018-10-12 2025-03-04 益方生物科技(上海)股份有限公司 甲状腺激素受体激动剂
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途

Also Published As

Publication number Publication date
EP4023641B1 (en) 2024-05-01
AU2013315017A1 (en) 2015-04-02
KR20210083381A (ko) 2021-07-06
CA3111317A1 (en) 2014-03-20
JP7038745B2 (ja) 2022-03-18
US9266861B2 (en) 2016-02-23
JP2024056793A (ja) 2024-04-23
JP2020109090A (ja) 2020-07-16
ES2907926T3 (es) 2022-04-27
US20160243126A1 (en) 2016-08-25
US20190381053A1 (en) 2019-12-19
WO2014043706A8 (en) 2017-10-19
US20180228807A1 (en) 2018-08-16
DK4406594T3 (da) 2025-11-03
IL288133A (en) 2022-01-01
MX364661B (es) 2019-05-03
IL259610A (en) 2018-07-31
PT4406594T (pt) 2025-11-28
FI4406594T3 (fi) 2025-11-26
IL320269A (en) 2025-06-01
KR20180131647A (ko) 2018-12-10
CN108101851A (zh) 2018-06-01
US20150203473A1 (en) 2015-07-23
AR092872A1 (es) 2015-05-06
JP6765408B2 (ja) 2020-10-07
TWI652260B (zh) 2019-03-01
JP2025179154A (ja) 2025-12-09
TWI681957B (zh) 2020-01-11
TW201425300A (zh) 2014-07-01
CA2884481A1 (en) 2014-03-20
TW202134217A (zh) 2021-09-16
RU2018128393A (ru) 2019-03-14
JP7436542B2 (ja) 2024-02-21
RU2668960C2 (ru) 2018-10-05
IL275393A (en) 2020-07-30
IL237628A0 (en) 2015-04-30
TW201906835A (zh) 2019-02-16
EP4023641A2 (en) 2022-07-06
JP6616688B2 (ja) 2019-12-04
EP3689853A1 (en) 2020-08-05
AU2013315017C1 (en) 2017-11-23
AU2013315017B2 (en) 2017-07-27
DK2895466T3 (da) 2020-06-08
CA3090070C (en) 2023-01-24
BR112015005891A2 (pt) 2017-08-08
NZ739645A (en) 2019-11-29
KR102138750B1 (ko) 2020-07-29
EP2895466A4 (en) 2016-08-10
DK3689853T3 (da) 2022-03-07
IL265030B (en) 2020-07-30
IL288133B1 (en) 2024-08-01
SG11201501907YA (en) 2015-04-29
US10376517B2 (en) 2019-08-13
TWI804870B (zh) 2023-06-11
KR101966490B1 (ko) 2019-08-14
MX2015003418A (es) 2016-04-04
EP2895466A1 (en) 2015-07-22
IL288133B2 (en) 2024-12-01
KR102363776B1 (ko) 2022-02-15
EP3689853B1 (en) 2021-11-24
WO2014043706A1 (en) 2014-03-20
BR122021024202B1 (pt) 2022-05-17
JP2020015739A (ja) 2020-01-30
RU2018128393A3 (enExample) 2019-04-16
CA3111317C (en) 2023-08-29
HK1212682A1 (en) 2016-06-17
US9968612B2 (en) 2018-05-15
EP4406594B1 (en) 2025-09-10
CN105008335A (zh) 2015-10-28
IL314360A (en) 2024-09-01
KR20150056630A (ko) 2015-05-26
US20230210856A1 (en) 2023-07-06
TW201946917A (zh) 2019-12-16
JP2019048856A (ja) 2019-03-28
IL259610B (en) 2020-06-30
JP2018080188A (ja) 2018-05-24
IL275393B (en) 2022-01-01
EP4406594A3 (en) 2024-11-06
US11564926B2 (en) 2023-01-31
NZ705827A (en) 2018-07-27
CA3090070A1 (en) 2014-03-20
JP2022078218A (ja) 2022-05-24
EP4023641A3 (en) 2022-09-14
JP6532931B2 (ja) 2019-06-19
ZA201501795B (en) 2021-10-27
IL314360B2 (en) 2025-09-01
MY170520A (en) 2019-08-08
TWI755628B (zh) 2022-02-21
MX395148B (es) 2025-03-24
ES2795450T3 (es) 2020-11-23
IN2015DN03133A (enExample) 2015-10-02
IL314360B1 (en) 2025-05-01
US20210161904A1 (en) 2021-06-03
IL237628B (en) 2019-07-31
JP6899413B2 (ja) 2021-07-07
US11986481B2 (en) 2024-05-21
CA2884481C (en) 2021-04-27
EP2895466B1 (en) 2020-03-25
SG10201705984XA (en) 2017-08-30
EP4406594A2 (en) 2024-07-31
CN105008335B (zh) 2018-12-21
RU2015114327A (ru) 2016-11-10
MX2018014924A (es) 2020-09-02
SG10202006058QA (en) 2020-08-28
US20240148742A1 (en) 2024-05-09
US10894050B2 (en) 2021-01-19
US20240122936A1 (en) 2024-04-18
JP2015535817A (ja) 2015-12-17

Similar Documents

Publication Publication Date Title
US11986481B2 (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
HK40113302A (en) Thyroid hormone analogs
HK40113302B (en) Thyroid hormone analogs
HK40077432B (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
HK40077432A (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
HK40033715A (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
HK40033715B (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
HK1212682B (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200225

Application number text: 1020187034908

Filing date: 20181130

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200325

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200504

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20201014

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200504

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20201014

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20200731

Comment text: Amendment to Specification, etc.

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20201201

Patent event code: PE09021S02D

AMND Amendment
PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20210525

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210427

Comment text: Final Notice of Reason for Refusal

Patent event code: PX06013S02I

Patent event date: 20201201

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20201113

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20201014

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200731

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20200504

X601 Decision of rejection after re-examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210625

Application number text: 1020187034908

Filing date: 20181130